[go: up one dir, main page]

NO20066074L - Irinotecanpreparat - Google Patents

Irinotecanpreparat

Info

Publication number
NO20066074L
NO20066074L NO20066074A NO20066074A NO20066074L NO 20066074 L NO20066074 L NO 20066074L NO 20066074 A NO20066074 A NO 20066074A NO 20066074 A NO20066074 A NO 20066074A NO 20066074 L NO20066074 L NO 20066074L
Authority
NO
Norway
Prior art keywords
irinotecan
mol
closed
salt
water phase
Prior art date
Application number
NO20066074A
Other languages
English (en)
Norwegian (no)
Inventor
Seigo Sawada
Takeshi Matsuzaki
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Ikuo Kato
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of NO20066074L publication Critical patent/NO20066074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20066074A 2004-06-01 2006-12-29 Irinotecanpreparat NO20066074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (fr) 2004-06-01 2005-05-31 Préparation d'irinotécan

Publications (1)

Publication Number Publication Date
NO20066074L true NO20066074L (no) 2007-02-28

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066074A NO20066074L (no) 2004-06-01 2006-12-29 Irinotecanpreparat

Country Status (24)

Country Link
US (1) US7846473B2 (fr)
EP (1) EP1752150B1 (fr)
JP (1) JP4885715B2 (fr)
KR (1) KR100889139B1 (fr)
CN (1) CN1960729B (fr)
AP (1) AP2255A (fr)
AR (1) AR049137A1 (fr)
AU (1) AU2005249314B2 (fr)
BR (1) BRPI0511753A (fr)
CA (1) CA2567857C (fr)
CR (1) CR8768A (fr)
EA (1) EA011612B1 (fr)
EC (1) ECSP067041A (fr)
ES (1) ES2594621T3 (fr)
GE (1) GEP20094620B (fr)
IL (1) IL179558A0 (fr)
MX (1) MXPA06013874A (fr)
NO (1) NO20066074L (fr)
NZ (1) NZ551748A (fr)
TN (1) TNSN06395A1 (fr)
TW (1) TWI362931B (fr)
UA (1) UA85099C2 (fr)
WO (1) WO2005117878A1 (fr)
ZA (1) ZA200610204B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107712A1 (fr) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes utiles pour l'administration de medicaments
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
JP2011520962A (ja) * 2008-05-19 2011-07-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 新規カチオン性脂質を含む方法及び組成物
WO2010058840A1 (fr) * 2008-11-20 2010-05-27 テルモ株式会社 Moyens pour libérer un mélange depuis un liposome et procédé pour évaluer des caractéristiques de libération
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
RU2526114C2 (ru) * 2009-12-03 2014-08-20 Цзянсу Хэнжуй Медицин Ко., Лтд. Липосомы иринотекана или его солей, способ их получения
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
TWI619496B (zh) 2011-11-03 2018-04-01 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2013312819A1 (en) * 2012-09-04 2015-03-26 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
CA2992789A1 (fr) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Traitement combine utilisant l'irinotecan liposomal et un inhibiteur de parp pour un traitement anticancereux
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
RS67289B1 (sr) 2015-10-16 2025-11-28 Ipsen Biopharm Ltd Stabilizacija farmaceutskih kompozicija kamptotecina
WO2018083470A1 (fr) * 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CA3231432A1 (fr) * 2021-10-15 2023-04-20 Tianyi Ke Composition contenant un medicament antitumoral, son procede de preparation et son utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JPH09504517A (ja) 1993-09-27 1997-05-06 スミスクライン・ビーチャム・コーポレイション カンプトテシン処方物
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
NZ511112A (en) 1998-09-16 2003-11-28 Alza Corp Lipsome-entrapped topoisomerase inhibitors
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
ATE430556T1 (de) 1999-06-25 2009-05-15 Terumo Corp Liposome
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO2002002078A2 (fr) * 2000-06-30 2002-01-10 Inex Pharmaceuticals Corporation Améliorations apportées à des encapsulations de camptothécines dans des liposomes et applications
WO2003028697A2 (fr) 2001-10-03 2003-04-10 Celator Technologies Inc. Chargement de liposome avec des ions metalliques
ATE345775T1 (de) * 2001-10-03 2006-12-15 Celator Pharmaceuticals Inc Zusammensetzungen zur verabreichung von arzneimittelkombinationen
US8518437B2 (en) * 2001-11-13 2013-08-27 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
DE60222580T2 (de) 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
US20060193902A1 (en) * 2003-04-02 2006-08-31 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
WO2005107712A1 (fr) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes utiles pour l'administration de medicaments
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Also Published As

Publication number Publication date
IL179558A0 (en) 2007-07-04
AU2005249314B2 (en) 2008-09-11
CN1960729A (zh) 2007-05-09
UA85099C2 (en) 2008-12-25
WO2005117878A1 (fr) 2005-12-15
AP2006003837A0 (en) 2006-12-31
CA2567857A1 (fr) 2005-12-15
BRPI0511753A (pt) 2008-01-02
EP1752150A1 (fr) 2007-02-14
ES2594621T3 (es) 2016-12-21
KR20070037440A (ko) 2007-04-04
AR049137A1 (es) 2006-06-28
EP1752150B1 (fr) 2016-08-31
ECSP067041A (es) 2006-12-29
TWI362931B (en) 2012-05-01
KR100889139B1 (ko) 2009-03-17
AU2005249314A1 (en) 2005-12-15
MXPA06013874A (es) 2007-04-25
TNSN06395A1 (en) 2008-02-22
CA2567857C (fr) 2009-12-22
GEP20094620B (en) 2009-02-25
EP1752150A4 (fr) 2012-06-20
US7846473B2 (en) 2010-12-07
US20080069868A1 (en) 2008-03-20
CN1960729B (zh) 2012-04-11
EA200602246A1 (ru) 2007-04-27
ZA200610204B (en) 2008-01-30
JP4885715B2 (ja) 2012-02-29
TW200600095A (en) 2006-01-01
EA011612B1 (ru) 2009-04-28
NZ551748A (en) 2010-02-26
AP2255A (en) 2011-07-21
JPWO2005117878A1 (ja) 2008-04-03
CR8768A (es) 2007-08-28

Similar Documents

Publication Publication Date Title
NO20066074L (no) Irinotecanpreparat
Kim et al. Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression
Stoimenovski et al. Enhanced membrane transport of pharmaceutically active protic ionic liquids
Machado et al. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective
Pata et al. Membrane solubilization by detergent: resistance conferred by thickness
AU4711296A (en) Method for loading lipid vesicles
NO883591L (no) Dermal administrasjonsform.
BRPI0506831A (pt) proteìnas de andaime de membrana
Todo et al. Permeation pathway of macromolecules and nanospheres through skin
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
Malovrh et al. Characterization of hemolytic activity of 3-alkylpyridinium polymers from the marine sponge Reniera sarai
ITMI20020189A1 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
Schrier Pathobiology of thalassemic erythrocytes
Daniels et al. Glucose and glycerol compared as osmotic agents for peritoneal dialysis
CN112716899B (zh) 一种防治主动脉夹层的仿生纳米药物及其制备方法
Sadzuka et al. Effective irinotecan (CPT‐11)‐containing liposomes: intraliposomal conversion to the active metabolite SN‐38
Matsuo et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis
Vitiello et al. The iAβ5p β-breaker peptide regulates the Aβ (25–35) interaction with lipid bilayers through a cholesterol-mediated mechanism
Flanigan How should dialysis fluid be individualized for the chronic hemodialysis patient?
Hoshi et al. Hydrogen ion-coupled transport of D-glucose by phlorizin-sensitive sugar carrier in intestinal brush-border membranes
Sato et al. Induction of the expression of cardioprotective proteins after mild-to-moderate consumption of alcohol
Heller et al. Changes in lipid bilayer structure caused by the helix-to-sheet transition of an HIV-1 gp41 fusion peptide derivative
Tokuoka et al. Circular dichroism studies on the interaction between human serum albumin and thyroxine
KR20210040505A (ko) 경피약물전달펩티드와 주름개선펩티드의 신규 접합 기능성 펩티드 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application